DAFNA Capital Management »

AtriCure shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of AtriCure (ATRC) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in AtriCure

Tip: Access up to 7 years of quarterly data

All positions including AtriCure held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in AtriCure by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2012-06-30 $943k 98k 9.61

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Cytokinetics Com New (CYTK)
Stereotaxis Com New (STXS)
Ideaya Biosciences (IDYA)
Syndax Pharmaceuticals (SNDX)
Ascendis Pharma A/s Sponsored Adr (ASND)
Karuna Therapeutics Ord
Revolution Medicines (RVMD)
Ishares Nasdaq Biotech Indx Etf (IBB)
Xenon Pharmaceuticals (XENE)
Merus N V (MRUS)
Blueprint Medicines (BPMC)
Day One Biopharmaceuticals I (DAWN)
Neurocrine Biosciences (NBIX)
Dex (DXCM)

View all positions for DAFNA Capital Management

Top funds holding AtriCure

Vanguard Group
Alliancebernstein
First Light Asset Management
Wellington Management Company
Fred Alger Management
Dimensional Fund Advisors
Credit Suisse
TimesSquare Capital Management
Fiera Capital Corporation
Bellevue Group
Jennifer Ranahan
Neuberger Berman Group
Daniel D. Thurber
Millennium Management
Bnp Paribas Investment Partners

View all funds holding AtriCure